Roche’s Tecentriq shows promise in early triple-negative breast cancer
Less patients who received the Tecentriq combination before surgery had evidence of tumour tissue detectable at the time of surgery
Read More
Tag: PD-L1
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Read More
NICE draft ‘no’ for Roche’s Tecentriq
The committee felt that comparison to existing treatments for the condition was “unreliable and lacked validity”.
Read More
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Read More
MSD’s Keytruda shows benefit in oesophageal cancer trial
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
Read More
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Read More
Study discovers immunotherapy could treat some aggressive prostate cancers
New research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances of survival, but could mean they are more likely to benefit from immunotherapy.
Read More
Keytruda extends survival in first-line head and neck cancer trial
MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
Read More
BMS’ Opdivo/Yervoy combo cleared for kidney cancer
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Read More
MSD’s Keytruda bags another trial success in NSCLC
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.
Read More
NICE u-turn sees Roche’s Tecentriq backed for lung cancer
Following an earlier negative decision NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.
Read More
Opdivo/Yervoy combo beats chemo on PFS in lung cancer
Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
